In this study, the results showed that the IC50 of the nanoparticles in PC9 cells was much lower compared to H1975 cells, consistent with previous reports that erlotonib may affects this molecular targets and inhibits EGFR-mutant PC9 cells but fails to achieve good results NSCLC cells with EGFR T790M mutation are obtained (Lv et al., 2018). This evidence concerns the gene EGFR and non-small cell lung carcinoma.